Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    873 result(s) found for: Anemia. Displaying page 3 of 44.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000765-37 Sponsor Protocol Number: P-CKD-01 Start Date*: 2007-05-10
    Sponsor Name:Pharmacosmos A/S
    Full Title: A non-comparative open-label study of Iron Oligosaccharide in Chronic Kidney Disease patients with a need for parenteral iron
    Medical condition: Patients with Chronic kidney disease who are in pre-dialysis or undergoing dialysis (either Peritoneal Dialysis or Haemodialysis), who may be treated with erythropoeisis stimulating agents and have...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002062 Anaemia iron deficiency LLT
    9.1 10018875 Haemodialysis LLT
    9.1 10061105 Dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003121-94 Sponsor Protocol Number: P-Monofer-IBD-02 Start Date*: 2011-12-14
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by a High Dosing Regimen in Subjects with Inflammatory Bowel Disease (PROMISE)
    Medical condition: Inflammatory Bowel Disease (IBD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001503-26 Sponsor Protocol Number: FER-CARS-03 Start Date*: 2008-10-17
    Sponsor Name:Vifor Pharma - Vifor (International) AG
    Full Title: EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure (EFFICACY-HF)
    Medical condition: Ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    9.1 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016727-53 Sponsor Protocol Number: P-Monofer-CIA-01 Start Date*: 2010-04-12
    Sponsor Name:Pharmacosmos A/S
    Full Title: A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjec...
    Medical condition: non-myeloid malignancies associated with chemotherapy induced anaemia (CIA).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064014 Cancer anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) SE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004568-37 Sponsor Protocol Number: INV543 Start Date*: 2018-11-30
    Sponsor Name:Nova Laboratories Limited
    Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia
    Medical condition: Sickle Cell Anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003846-41 Sponsor Protocol Number: AFX01-10 Start Date*: 2008-03-20
    Sponsor Name:Affymax, Inc.
    Full Title: An Open-label, Multi-center, Extension Study to Evaluate the Safety and Tolerability of AF37702 Injection (Hematide™) for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidn...
    Medical condition: Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000902-55 Sponsor Protocol Number: RATGAA07 Start Date*: 2007-09-19
    Sponsor Name:EBMT (European group for Blood and Marrow Transplantation)
    Full Title: Prospective Phase II study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patie...
    Medical condition: Acquired severe aplastic anaemia and transfusion dependent non-severe aplastic anaemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10002274 Anemia aplastic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004153-28 Sponsor Protocol Number: AFX01-14 Start Date*: 2009-06-23
    Sponsor Name:Affymax Inc.
    Full Title: A Phase 3, Randomized, Active-controlled, Open-label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously ...
    Medical condition: Maintenance treatment of anemia in hemodialysis patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003710-13 Sponsor Protocol Number: NL41820.018.12 Start Date*: 2013-03-21
    Sponsor Name:Academic Medical Center
    Full Title: C1-inhibitor improves efficacy of red blood cell transfusion in patients suffering from autoimmune hemolytic anemia – an open-labeled pilot trial
    Medical condition: AutoImmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005180-27 Sponsor Protocol Number: 1517-CL-0608 Start Date*: 2013-06-24
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
    Medical condition: Anemia in CKD patients not on dialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) HU (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) EE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000348-22 Sponsor Protocol Number: KER047-IR-201 Start Date*: 2021-08-10
    Sponsor Name:Keros Therapeutics, Inc.
    Full Title: A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA
    Medical condition: Iron-Refractory Iron-Deficiency Anemia (IRIDA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005889-40 Sponsor Protocol Number: ABR-15108 Start Date*: 2007-08-14
    Sponsor Name:Academic Medical Centre
    Full Title: N-Acetylcysteine for Treatment of Sickle Cell Disease
    Medical condition: Patients homozygous for sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040644 Sickle cell disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017091-25 Sponsor Protocol Number: P081110 Start Date*: 2010-07-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Quantification de la régression de l'albuminurie et de l'atteinte endothéliale dans une population de patients drépanocytaires homozygotes hyperfiltrants traités par inhibiteurs du système rénine-...
    Medical condition: Drépanocytose homozygote présentant une microalbuminurie associée à une hyperfiltration glomérulaire
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040644 drépanocytose PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003601-66 Sponsor Protocol Number: CSEG101ANL01T Start Date*: 2021-07-14
    Sponsor Name:Amsterdam UMC - AMC
    Full Title: The Effect of Crizanlizumab on Cerebral Perfusion and Oxygenation in Sickle Cell Patients
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001351-13 Sponsor Protocol Number: APHP201133 Start Date*: 2021-11-26
    Sponsor Name:Assistance Publique des Hôpitaux de Paris(AP-HP)
    Full Title: Interest of famotidine in reducing endothelial expression of P-selectin in children with sickle cell disease: pilot study, single-center, prospective, non-comparative
    Medical condition: major sickle cell syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001585-36 Sponsor Protocol Number: AMC_SMILE_1.0 Start Date*: 2022-07-05
    Sponsor Name:Amsterdam UMC
    Full Title: EffectS of L-glutaMIne on oxIdative stress, sickLE erythrocyte viability, inflammation and endothelial activity in sickle cell disease (SMILE trial)
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016728-29 Sponsor Protocol Number: P-Monofer-CKD-02 Start Date*: 2010-02-03
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Phase III, randomized, comparative, open-label study of intravenous Iron Isomaltoside 1000 (Monofer®) administered by infusions or repeated bolus injections in comparison with oral Iron Sulphate ...
    Medical condition: Non-dialysis dependent chronic kidney disease and with renal-related anaemia (NDD-CKD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.0 10005329 - Blood and lymphatic system disorders 10022974 Iron deficiency anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed) IE (Completed) DE (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004045-25 Sponsor Protocol Number: GBT440-034 Start Date*: 2018-04-17
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022133-28 Sponsor Protocol Number: AMAG-FER-CKD-401 Start Date*: 2013-08-12
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, with MRI Substudy, of Repeated Doses of Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Defic...
    Medical condition: Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10022974 Iron deficiency anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002021-11 Sponsor Protocol Number: 1VIT14039 Start Date*: 2016-07-13
    Sponsor Name:Luitpold Pharmaceuticals, Inc.
    Full Title: IRON CLAD: Can Iron Lessen Anemia Due to cancer and chemotherapy: A multicenter, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxyma...
    Medical condition: cancer- and chemotherapy-related anemia
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004851 10002272 Anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 15:10:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA